These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15996257)

  • 21. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol.
    Rickels MR; Liu C; Shlansky-Goldberg RD; Soleimanpour SA; Vivek K; Kamoun M; Min Z; Markmann E; Palangian M; Dalton-Bakes C; Fuller C; Chiou AJ; Barker CF; Luning Prak ET; Naji A
    Diabetes; 2013 Aug; 62(8):2890-7. PubMed ID: 23630300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.
    Maffi P; Bertuzzi F; De Taddeo F; Magistretti P; Nano R; Fiorina P; Caumo A; Pozzi P; Socci C; Venturini M; del Maschio A; Secchi A
    Diabetes Care; 2007 May; 30(5):1150-5. PubMed ID: 17259471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the number of infusions on 2-year results of islet-after-kidney transplantation in the GRAGIL network.
    Borot S; Niclauss N; Wojtusciszyn A; Brault C; Demuylder-Mischler S; Müller Y; Giovannoni L; Parnaud G; Meier R; Badet L; Bayle F; Frimat L; Kessler L; Morelon E; Penfornis A; Thivolet C; Toso C; Morel P; Bosco D; Colin C; Benhamou PY; Berney T;
    Transplantation; 2011 Nov; 92(9):1031-8. PubMed ID: 21926944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
    Tan J; Yang S; Cai J; Guo J; Huang L; Wu Z; Chen J; Liao L
    Diabetes; 2008 Oct; 57(10):2666-71. PubMed ID: 18633105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
    Posselt AM; Bellin MD; Tavakol M; Szot GL; Frassetto LA; Masharani U; Kerlan RK; Fong L; Vincenti FG; Hering BJ; Bluestone JA; Stock PG
    Am J Transplant; 2010 Aug; 10(8):1870-80. PubMed ID: 20659093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful islet transplantation for patients with diabetes--fact or fantasy?
    Robertson RP
    N Engl J Med; 2000 Jul; 343(4):289-90. PubMed ID: 10911012
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of the immunosuppressive regime of Edmonton protocol on the long-term in vitro insulin secretion from islets of two different species and age categories.
    Hyder A; Laue C; Schrezenmeir J
    Toxicol In Vitro; 2005 Jun; 19(4):541-6. PubMed ID: 15826812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Living donor islet transplantation, the alternative approach to overcome the obstacles limiting transplant.
    Iwanaga Y; Matsumoto S; Okitsu T; Noguchi H; Nagata H; Yonekawa Y; Yamada Y; Fukuda K; Tsukiyama K; Tanaka K
    Ann N Y Acad Sci; 2006 Oct; 1079():335-9. PubMed ID: 17130575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
    Posselt AM; Szot GL; Frassetto LA; Masharani U; Tavakol M; Amin R; McElroy J; Ramos MD; Kerlan RK; Fong L; Vincenti F; Bluestone JA; Stock PG
    Transplantation; 2010 Dec; 90(12):1595-601. PubMed ID: 20978464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International trial of the Edmonton protocol for islet transplantation.
    Shapiro AM; Ricordi C; Hering BJ; Auchincloss H; Lindblad R; Robertson RP; Secchi A; Brendel MD; Berney T; Brennan DC; Cagliero E; Alejandro R; Ryan EA; DiMercurio B; Morel P; Polonsky KS; Reems JA; Bretzel RG; Bertuzzi F; Froud T; Kandaswamy R; Sutherland DE; Eisenbarth G; Segal M; Preiksaitis J; Korbutt GS; Barton FB; Viviano L; Seyfert-Margolis V; Bluestone J; Lakey JR
    N Engl J Med; 2006 Sep; 355(13):1318-30. PubMed ID: 17005949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in insulin sensitivity after human islet transplantation for type 1 diabetes.
    Rickels MR; Kong SM; Fuller C; Dalton-Bakes C; Ferguson JF; Reilly MP; Teff KL; Naji A
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1780-5. PubMed ID: 24085506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid-Free Immune Suppression Impairs Glycemic Control in a Healthy Cynomolgus Monkey.
    Berman DM; Ruiz P; Blandino-Rosano M; Bernal-Mizrachi E; Kenyon NS
    Cell Transplant; 2019 Mar; 28(3):262-268. PubMed ID: 30675800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation.
    Hafiz MM; Faradji RN; Froud T; Pileggi A; Baidal DA; Cure P; Ponte G; Poggioli R; Cornejo A; Messinger S; Ricordi C; Alejandro R
    Transplantation; 2005 Dec; 80(12):1718-28. PubMed ID: 16378067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study.
    Vantyghem MC; Chetboun M; Gmyr V; Jannin A; Espiard S; Le Mapihan K; Raverdy V; Delalleau N; Machuron F; Hubert T; Frimat M; Van Belle E; Hazzan M; Pigny P; Noel C; Caiazzo R; Kerr-Conte J; Pattou F;
    Diabetes Care; 2019 Nov; 42(11):2042-2049. PubMed ID: 31615852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
    Zoso A; Serafini P; Lanzoni G; Peixoto E; Messinger S; Mantero A; Padilla-Téllez ND; Baidal DA; Alejandro R; Ricordi C; Inverardi L
    PLoS One; 2016; 11(6):e0157245. PubMed ID: 27285580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes.
    Bellin MD; Kandaswamy R; Parkey J; Zhang HJ; Liu B; Ihm SH; Ansite JD; Witson J; Bansal-Pakala P; Balamurugan AN; Papas KK; Sutherland DE; Moran A; Hering BJ
    Am J Transplant; 2008 Nov; 8(11):2463-70. PubMed ID: 18808408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade.
    Blau JE; Abegg MR; Flegel WA; Zhao X; Harlan DM; Rother KI
    Am J Transplant; 2015 Nov; 15(11):2995-3001. PubMed ID: 26184712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.
    Toso C; Morel P; Bucher P; Mathe Z; Demuylder-Mischler S; Bosco D; Berney T; Oberholzer J; Shapiro J; Oberholzer J; Philippe J
    Transplantation; 2003 Oct; 76(7):1133-4. PubMed ID: 14557767
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.